Marinus Pharmaceuticals Inc. (MRNS) NASDAQ
$5.80 0 (0.00%)
Market Cap: $215.76M
As of 08/15/22 11:16 AM EDT. Market open.
Marinus Pharmaceuticals Inc. (MRNS) NASDAQ
$5.80 0 (0.00%)
Market Cap: $215.76M
As of 08/15/22 11:16 AM EDT. Market open.
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms ... read more
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
69
CEO Compensation (Base)
$520,000
Address
.
PRICE CHART
From:
To:
NEWS
KEY STATS
Open
$5.95
Previous Close
$5.80
Days Range
$5.75 - $5.93
52 week range
$3.97 - $13.15
Volume
40,839
Avg. Volume (30 days)
190,108
Market Cap
$215.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
37,199,150
Open
$5.95
Previous Close
$5.80
Days Range
$5.75 - $5.93
52 week range
$3.97 - $13.15
Volume
40,839
Avg. Volume (30 days)
190,108
Market Cap
$215.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
37,199,150
Open in:
Open in:
INSIDER TRANSACTIONS FOR MARINUS PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| VITULLO NICOLE | Director | Mar 15, 2021 | Sale | $15.87 | 4,250 | 67,447 | 0 | Mar 16, 2021, 04:58 PM |
| Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Option Exercise | $4.16 | 35,927 | 149,456 | 53,644 | Mar 11, 2021, 04:04 PM |
| Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Sale | $17.80 | 40,356 | 718,337 | 13,288 | Mar 11, 2021, 04:04 PM |
| Smith Edward F | CFO | Jan 30, 2020 | Sale | $2.05 | 2,380 | 4,879 | 17,717 | Feb 03, 2020, 06:29 PM |
| Braunstein Scott | Chief Executive Officer | Dec 13, 2019 | Buy | $1.25 | 100,000 | 125,000 | 100,000 | Dec 13, 2019, 04:08 PM |
| Smith Edward F | CFO | May 16, 2019 | Sale | $5.03 | 24,211 | 121,781 | 20,097 | May 20, 2019, 04:20 PM |
| Cashman Christopher Michael | CEO | Mar 18, 2019 | Option Exercise | $1.04 | 31,662 | 32,928 | 271,423 | Mar 20, 2019, 05:57 PM |
| Cashman Christopher Michael | CEO | Jan 28, 2019 | Sale | $3.13 | 8,142 | 25,484 | 239,761 | Jan 30, 2019, 04:09 PM |
| Smith Edward F | CFO | Jan 29, 2019 | Sale | $3.06 | 2,492 | 7,626 | 44,308 | Jan 30, 2019, 04:08 PM |
| Smith Edward F | CFO | Jan 29, 2018 | Sale | $7.91 | 3,000 | 23,730 | 49,800 | Jan 29, 2018, 08:00 PM |
| Cashman Christopher Michael | CEO | Jan 18, 2018 | Sale | $6.28 | 9,566 | 60,074 | 247,903 | Jan 22, 2018, 08:41 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 19, 2017 | Sale | $7.43 | 150,000 | 1,114,670 | 4,032,682 | Dec 19, 2017, 08:30 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 18, 2017 | Sale | $7.50 | 300,000 | 2,251,440 | 4,127,453 | Dec 19, 2017, 08:30 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 15, 2017 | Sale | $8.10 | 822,547 | 6,658,691 | 4,530,335 | Dec 19, 2017, 08:30 PM |
| Mehra Anand | 10% Owner | Oct 20, 2016 | Sale | $1.39 | 750,683 | 1,042,699 | 1,134,851 | Oct 24, 2016, 04:49 PM |
| Canaan VII LP | 10% Owner | Aug 05, 2016 | Sale | $1.50 | 129,204 | 193,806 | 1,870,733 | Aug 09, 2016, 10:03 AM |
| Canaan VII LP | 10% Owner | Aug 08, 2016 | Sale | $1.50 | 19,950 | 29,925 | 1,850,783 | Aug 09, 2016, 10:03 AM |
| Canaan VII LP | 10% Owner | Aug 04, 2016 | Sale | $1.50 | 3,329 | 4,994 | 1,999,937 | Aug 05, 2016, 10:18 AM |
| Canaan VII LP | 10% Owner | Aug 03, 2016 | Sale | $1.50 | 142,254 | 213,381 | 2,003,266 | Aug 05, 2016, 10:18 AM |
| Canaan VII LP | 10% Owner | Jul 29, 2016 | Sale | $1.71 | 24,540 | 41,963 | 2,145,520 | Aug 02, 2016, 12:22 PM |
| Canaan VII LP | 10% Owner | Jul 26, 2016 | Sale | $1.81 | 20,380 | 36,888 | 2,170,269 | Jul 27, 2016, 04:30 PM |
| Canaan VII LP | 10% Owner | Jul 27, 2016 | Sale | $1.80 | 209 | 376 | 2,170,060 | Jul 27, 2016, 04:30 PM |
| Canaan VII LP | 10% Owner | Jul 25, 2016 | Sale | $1.86 | 137,617 | 255,968 | 2,190,649 | Jul 26, 2016, 10:08 AM |
| Canaan VII LP | 10% Owner | Jul 22, 2016 | Sale | $1.94 | 133,133 | 258,278 | 2,328,266 | Jul 26, 2016, 10:08 AM |
| Cashman Christopher Michael | President and CEO | Feb 09, 2016 | Option Exercise | $1.04 | 24,684 | 25,671 | 140,769 | Feb 11, 2016, 05:17 PM |
| Cashman Christopher Michael | President and CEO | Nov 06, 2015 | Buy | $5.61 | 3,561 | 19,977 | 116,085 | Feb 11, 2016, 05:17 PM |
| Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Feb 04, 2016, 06:48 PM |
| Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Sep 28, 2015, 08:12 PM |
| MAYLEBEN TIMOTHY M | Director | Jul 16, 2015 | Option Exercise | $1.04 | 42,550 | 44,252 | 42,550 | Jul 17, 2015, 04:01 PM |
| Cashman Christopher Michael | President and CEO | Jul 01, 2015 | Option Exercise | $1.04 | 14,086 | 14,649 | 112,524 | Jul 02, 2015, 04:08 PM |
| Bloch Stephen M | Director | Jun 10, 2015 | Option Exercise | $1.04 | 3,000 | 3,120 | 3,000 | Jun 11, 2015, 05:26 PM |
| Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Option Exercise | $1.04 | 30,000 | 31,200 | 30,000 | Apr 23, 2015, 04:48 PM |
| Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Sale | $9.48 | 30,000 | 284,511 | 0 | Apr 23, 2015, 04:48 PM |
| Cashman Christopher Michael | PRESIDENT AND CEO | Mar 06, 2015 | Option Exercise | $1.04 | 17,608 | 18,312 | 98,438 | Mar 10, 2015, 01:16 PM |
| Cashman Christopher Michael | PRESIDENT AND CEO | Oct 08, 2014 | Option Exercise | $1.04 | 80,830 | 84,063 | 80,830 | Oct 09, 2014, 04:05 PM |
| Domain Partners VI, L.P. | 10% Owner | Aug 05, 2014 | Buy | $8.00 | 419,744 | 3,357,952 | 2,476,886 | Aug 07, 2014, 03:06 PM |
| Mehra Anand | Director | Aug 05, 2014 | Buy | $8.00 | 750,683 | 6,005,464 | 1,859,639 | Aug 07, 2014, 12:43 PM |
| Canaan VII L P | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
| Bloch Stephen M | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| VITULLO NICOLE | Director | 03/15/2021 | 67,447 |
| Smith Edward F | Former VP, CFO & Treasurer | 03/09/2021 | 149,456 |
| Smith Edward F | Former VP, CFO & Treasurer | 03/09/2021 | 718,337 |
| Smith Edward F | CFO | 01/30/2020 | 4,879 |
| Braunstein Scott | Chief Executive Officer | 12/13/2019 | 125,000 |
| Smith Edward F | CFO | 05/16/2019 | 121,781 |
| Cashman Christopher Michael | CEO | 03/18/2019 | 32,928 |
| Cashman Christopher Michael | CEO | 01/28/2019 | 25,484 |
| Smith Edward F | CFO | 01/29/2019 | 7,626 |
| Smith Edward F | CFO | 01/29/2018 | 23,730 |
| Cashman Christopher Michael | CEO | 01/18/2018 | 60,074 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/19/2017 | 1,114,670 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/18/2017 | 2,251,440 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/15/2017 | 6,658,691 |
| Mehra Anand | 10% Owner | 10/20/2016 | 1,042,699 |
| Canaan VII LP | 10% Owner | 08/05/2016 | 193,806 |
| Canaan VII LP | 10% Owner | 08/08/2016 | 29,925 |
| Canaan VII LP | 10% Owner | 08/04/2016 | 4,994 |
| Canaan VII LP | 10% Owner | 08/03/2016 | 213,381 |
| Canaan VII LP | 10% Owner | 07/29/2016 | 41,963 |
| Canaan VII LP | 10% Owner | 07/26/2016 | 36,888 |
| Canaan VII LP | 10% Owner | 07/27/2016 | 376 |
| Canaan VII LP | 10% Owner | 07/25/2016 | 255,968 |
| Canaan VII LP | 10% Owner | 07/22/2016 | 258,278 |
| Cashman Christopher Michael | President and CEO | 02/09/2016 | 25,671 |
| Cashman Christopher Michael | President and CEO | 11/06/2015 | 19,977 |
| Bloch Stephen M | Director | 09/28/2015 | 41,132 |
| Bloch Stephen M | Director | 09/28/2015 | 41,132 |
| MAYLEBEN TIMOTHY M | Director | 07/16/2015 | 44,252 |
| Cashman Christopher Michael | President and CEO | 07/01/2015 | 14,649 |
| Bloch Stephen M | Director | 06/10/2015 | 3,120 |
| Farfel Gail M | Chief Clinical Dev & Reg Offic | 04/21/2015 | 31,200 |
| Farfel Gail M | Chief Clinical Dev & Reg Offic | 04/21/2015 | 284,511 |
| Cashman Christopher Michael | PRESIDENT AND CEO | 03/06/2015 | 18,312 |
| Cashman Christopher Michael | PRESIDENT AND CEO | 10/08/2014 | 84,063 |
| Domain Partners VI, L.P. | 10% Owner | 08/05/2014 | 3,357,952 |
| Mehra Anand | Director | 08/05/2014 | 6,005,464 |
| Canaan VII L P | Director | 08/05/2014 | 5,000,000 |
| Bloch Stephen M | Director | 08/05/2014 | 5,000,000 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2021
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2021
-0.01%
1Q
03/31/2021
0.17%
3Q
12/31/2020
34.45%
4Q
09/30/2020
42.45%
5Q
12/31/2019
-32.74%
8Q
09/30/2019
-30.18%
9Q
06/30/2019
-30.16%
10Q
03/31/2019
-30.12%
11Q
12/31/2018
-10.35%
12Q
09/30/2018
-9.23%
13Q
06/30/2018
-9.21%
14Q
03/31/2018
-9.19%
15Q
Load More